×
  • Life - Health & Wellness
  • Updated: January 15, 2024

Research Exploring ACE-031 Peptide

Research Exploring ACE-031 Peptide

ACE 031 is a soluble activin receptor kind 2B (ActRIIB) protein, an intrinsic molecule, and IgG1-Fc. Studies suggest the ACE-031 peptide may potentially be effective in blocking the natural production of myostatin, a protein secreted by muscles that may act as a growth factor to control muscle size in mice.

ACE 031 Peptide: What is it?

The ActRIIB receptor and antibody from mice were fused to create a recombinant fusion protein called ACE-031 Peptide.

Research suggests that the muscles may get stronger by decreasing the off signal, which may inhibit muscle synthesis. ACE-031 has been suggested in studies to inhibit these ligands' secretion, promoting rapid and substantial muscle development.

Animal studies purport that ACE-031's potential may improve muscular hypertrophy and muscle strength. Data suggests it may also protect against muscle atrophy and neuromuscular disorders. This peptide has been utilized extensively in laboratory studies for its potential in the context of neuromuscular diseases and increased muscle growth.

ACE 031 Peptide and Muscle

The CEO of Acceleron, John Knopf, Ph., has suggested that "ACE-031 holds great potential as an agent for mice affected by neuromuscular diseases like muscular dystrophy and amyotrophic lateral sclerosis (ALS)".

Mice rely heavily on their muscles, and disorders like amyotrophic lateral sclerosis and muscular dystrophy have been linked to fatal declines in muscle mass. Scientists are gaining a better understanding of ACE-031 and its potential use in stopping muscle atrophy.

Studies in animals with renal failure and cancer cachexia have proposed that myostatin-blocking agents like ACE 031 may reduce muscle atrophy and strength loss. Researchers have also speculated that they may improve insulin sensitivity, decrease inflammation, lessen body fat percentage, and stimulate bone formation and repair. Muscle mass was suggested to be increased by ACE-031 in mice despite no discernible effect on fiber type expression.

ACE 031 Peptide and Neuromuscular Studies

Results from a Phase 1 experimental study of ACE-031 suggesting the peptide's potential to increase lean body mass were recently announced by Acceleron Pharma, a biopharmaceutical company developing innovative technology that may possibly stimulate the development of cells and tissues, including muscle, red blood cells, and bone.

Acceleron's Chief Medical Officer, Matthew Shermice, M.D., expressed his excitement over the Phase 1 clinical trial results for ACE-031. "We are excited that this ACE-031 Phase 1 clinical trial generated substantial amounts of encouraging data and clear signs of biological activity on muscle, bone, and fat," he said. Increases in bone formation indicators and favorable alterations in fat mass biomarkers accompanied by increases in lean body mass and muscle volume were hypothesized with ACE-031. Based on these findings, researchers have begun a Phase 1 multiple-concentration trial and look forward to the future development of ACE-031 in mice suffering from neuromuscular illnesses."

ACE 031 Peptide Properties

Researchers may now have a potent tool in ACE-031, a soluble version of the activin receptor type IIB (ActRIIB), to investigate the activin/myostatin pathway's function in muscle growth and development. Scientists theorize that the peptide's possible inhibitory action on activin and myostatin and its prospective uses in studying muscle wasting illnesses and other ailments may set it apart from existing research tools.

ACE-031 Peptide and Cellular and Molecular Biology

When studying the cellular and molecular factors that control muscle growth and development, ACE-031 is proposed as an important tool. It has been hypothesized that ACE-031 may be useful for studying the control of muscle hypertrophy and strength since it may possibly block the function of myostatin and activin. This knowledge might lead to the creation of novel approaches for managing illnesses of the skeletal muscle and enhancing the general health and well-being of many animal species.

ACE 031 Peptide Synthesis and Alterations

ActRIIB's extracellular domain was fused to a immunoglobulin Fc domain to create and optimize ACE-031. This union has been purported to produce a soluble and persistent receptor that may bind to and antagonize myostatin and activin. Studies suggest that ACE-031 is a powerful research tool for researching the activin/myostatin system since its stability, affinity, and potency have been enhanced by peptide synthesis and protein engineering.

ACE-031 Peptide: Prospects for Further Study 

Many interesting avenues may be pursued as a study on ACE-031 continues. The potential of ACE-031 on different kinds of muscle tissue, the presence of synergistic effects with other growth factors and signaling pathways, and the best presentation for diverse animal models are all things that need to be investigated. Findings from this study may have far-reaching effects on the knowledge of muscle biology and research in the field of muscular atrophy.

Researchers interested in further studying ACE-031 Peptide may find it for sale at biotechpeptides.com, the highest quality, most reputable online seller.

References

[i]  “Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys With Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial,” Craig Campbel, Hugh J McMillan, Jean K Mah, Mark Tarnopolsky, Kathryn Selby, Ty McClure, Dawn M Wilson, Matthew L Shermice, Diana Escolar, Kenneth M Attie  https://pubmed.ncbi.nlm.nih.gov/27462804/

[ii] “ACE-031 for the Treatment of Duchenne Muscular Dystrophy,” https://www.clinicaltrialsarena.com/projects/ace031forthetreatmen/

[iii] “Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial,” https://www.flagshippioneering.com/press/acceleron-pharmas-ace-031-increases-lean-body-mass-phase-1-single-dose-clinical-trial

 

Related Topics

Join our Telegram platform to get news update Join Now

0 Comment(s)

See this post in...

Notice

We have selected third parties to use cookies for technical purposes as specified in the Cookie Policy. Use the “Accept All” button to consent or “Customize” button to set your cookie tracking settings